GALNT3 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL7980209	1.00	1/20
SCHEMBL29370098	1.00	1/20
SCHEMBL26768213	0.79	1/20
SCHEMBL7987277	0.69	1/20
SCHEMBL2357304	0.68	1/20
SCHEMBL29466713	0.68	1/20
SCHEMBL29827270	0.68	1/20
SCHEMBL17949557	0.66	1/20
SCHEMBL7984298	0.66	1/20
SCHEMBL9748319	0.61	1/20
SCHEMBL21517158	0.61	1/20
SCHEMBL3874869	0.61	1/20
SCHEMBL15285080	0.61	1/20
SCHEMBL31414410	0.61	1/20
SCHEMBL7330918	0.60	1/20
SCHEMBL22431062	0.59	1/20
SCHEMBL1444851	0.58	1/20
SCHEMBL30451609	0.58	1/20
SCHEMBL5351976	0.58	1/20
SCHEMBL7227954	0.57	1/20

Clinical trials — most relevant to GALNT3 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
A Safety and Efficacy Study of Fabrazyme® Replacement Therapy in Patients With Cardiac Fabry Disease	PHASE4	COMPLETED
A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis	PHASE1/PHASE2	RECRUITING
Multi-Center Study of ManNAc for GNE Myopathy	PHASE2	ACTIVE_NOT_RECRUITING
A Study of GlcNAc on Tear Production in NGLY1-CDDG	PHASE2	ACTIVE_NOT_RECRUITING
Study of Safety, Tolerability and Efficacy of PBGM01 in Pediatric Participants With GM1 Gangliosidosis	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
A Study to Evaluate the Safety, Tolerability and Efficacy of BMN 110 in Subjects With Mucopolysaccharidosis IVA	PHASE1/PHASE2	COMPLETED
A Phase 1 Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ManNAc in Subjects With Primary Podocyte Diseases	PHASE1	COMPLETED
Glycosylation in Patients With Galactosaemia	nan	COMPLETED
Inflammatory Pathways and Cardiac Growth Factors Associated With Fabry Disease Cardiomyopathy	nan	UNKNOWN
Institution of an Italian Multicenter Database of Patients Affected by Diseases of Phosphate Metabolism	nan	NOT_YET_RECRUITING
GALNT4 in Patients With Acute Coronary Syndrome	nan	COMPLETED
Screening of Fabry Disease in Patients With GI Symptoms	nan	UNKNOWN
Biomarker for Mucolipidosis Disorder Type I, II, III, IV (BioML)	nan	WITHDRAWN
A Retrospective Study to Identify New Omics Biomarkers of Chronic/Persistent Low Back Pain	nan	COMPLETED
Genome Environment Microbiome and Metabolome in Autism Study	nan	COMPLETED
Fibrosis, Inflammation, Oxygenation of Renal Tissue In FabrY Disease	nan	RECRUITING
BMN 110 US Expanded Access Program	nan	APPROVED_FOR_MARKETING
the Role of cArdiac Inflammation, endoThelial Dysfunction, and FIbrosis in fabrY Disease	nan	RECRUITING
Using D-Galactose as a Food Supplement in Congenital Disorders of Glycosylation	nan	COMPLETED
Biomarker for Patients With Fabry Disease (BioFabry)	nan	WITHDRAWN
Registry Gangliosidoses	nan	UNKNOWN
Canadian Fabry Disease Initiative (CFDI) National Registry	nan	RECRUITING
Evaluation of Blood Protein O-GlcNAcylation Levels in Children	nan	RECRUITING
A Natural History Study of Patients With GNE Myopathy and GNE-Related Diseases	nan	COMPLETED
Biomarkers and Cardiac Imaging Diagnostic Assay for Monitoring Patients With Fabry Disease	nan	RECRUITING
Italian Anderson Fabry Disease Cardiovascular Registry	nan	RECRUITING
EXpanding Prenatal Cell Free DNA Screening Across moNogenic Disorders (EXPAND)	nan	RECRUITING
A Prospective Trial to Identify Biomarkers Involved in the Transition From Acute to Persistent Chronic Low Back Pain	nan	UNKNOWN
A Study Measuring Substances Potentially Indicating Bone Problems in Adults With Type 1 Gaucher Condition	nan	COMPLETED
Galectin-3 in Septic and Non-septic Acute Kidney Injury	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a GALNT3 binder may also engage these)

Protein	Name	Similarity
P70419	—	1.000	P70419 →
H0ZAB5	—	1.000	H0ZAB5 →
Q6WV20	—	0.999	Q6WV20 →
Q5EA41	—	0.997	Q5EA41 →
Q8C7U7	—	0.997	Q8C7U7 →
Q6P6V1	—	0.997	Q6P6V1 →
Q8MV48	—	0.997	Q8MV48 →
Q921L8	—	0.997	Q921L8 →
Q6WV17	—	0.997	Q6WV17 →
Q8BVG5	—	0.996	Q8BVG5 →
O61394	—	0.996	O61394 →
S5S833	—	0.996	S5S833 →
Q6DJR8	—	0.996	Q6DJR8 →
Q29121	—	0.995	Q29121 →
GALNT13	Polypeptide N-acetylgalactosaminyltransferase 13	0.995	landscape →
Q8CF93	—	0.995	Q8CF93 →
Q9D4M9	—	0.995	Q9D4M9 →
Q6UE39	—	0.994	Q6UE39 →
O08912	—	0.994	O08912 →
Q8MRC9	—	0.994	Q8MRC9 →
Q8IXK2	—	0.994	Q8IXK2 →
Q95JX4	—	0.994	Q95JX4 →
GALNT1	Polypeptide N-acetylgalactosaminyltransferase 1	0.994	landscape →
Q8I136	—	0.993	Q8I136 →
Q8NCW6	—	0.993	Q8NCW6 →
O61397	—	0.993	O61397 →
Q8N4A0	—	0.993	Q8N4A0 →
GALNT6	Polypeptide N-acetylgalactosaminyltransferase 6	0.993	landscape →
O45947	—	0.993	O45947 →
GALNT14	Polypeptide N-acetylgalactosaminyltransferase 14	0.993	landscape →